Lymphoma
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/Yescarta.jpg)
Yescarta, also known as axicabtagene ciloleucel, is a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy that has been hailed as a significant breakthrough in the treatment of certain types of lymphoma.
![image](https://www.medtourcn.com/wp-content/uploads/2024/09/微信截图_20240903145235.jpg)
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL) #MantleCellLymphoma #MCL #Lymphoma #RRMCL #RelmaCel #CART #Non-HodgkinLymphoma #NHL In the global cancer treatment landscape, the advancements in CAR-T cell therapy are remarkable, particularly in the treatment of relapsed and refractory Mantle Cell Lymphoma (MCL). China’s CAR-T therapy, Relma-cel, Read More
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240830161806.jpg)
**China’s CAR-T Therapy Approved for New Indication: Bringing New Hope to Relapsed Mantle Cell Lymphoma Patients** The approval of Relmacabtagene Autoleucel brings renewed hope for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). MCL is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL). Despite advancements in treatment options over recent years, Read More